| **Subgroup** | **Study** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| Age | Cook, 2005 (WHS)60\* | Group | 45-54 years | 55-64 years | ≥65 years | Between Group Difference |
| ASA | 671/12010 (6%) | 515/5876 (9%) | 252/2048 (12%) | 45-54 years: ASA vs. No ASA: RR 1.04 (95% CI, 0.93 to 1.16), p=0.49‡  55-64 years: ASA vs. No ASA: RR 1.00 (95% CI, 0.89 to 1.14), p=0.94‡  ≥ 65 years: ASA vs. No ASA: RR 0.93 (95% CI, 0.78 to 1.11), p=0.42‡ |
| No ASA | 647/12015 (5%) | 512/5878 (9%) | 268/2049 (13%) |
| Rothwell, 201210  (IPD MA)  Cancer <3 years | Group | Age <60 years | Age ≥60 years | -- | Between Group Difference |
| ASA | 115/NR (NR) | 330/NR (NR) | -- | Age < 60 years: ASA vs. No ASA: OR 0.83 (95% CI, 0.65 to 1.07), p=0.14  Age ≥ 60 years: ASA vs. No ASA: OR 1.08 (95% CI, 0.92 to 1.27), p=0.32 |
| No ASA | 141/NR (NR) | 301/NR (NR) |
| Rothwell, 201210  (IPD MA)  Cancer ≥3 years | ASA | 105/NR (NR) | 219/NR (NR) | -- | Age < 60 years: ASA vs. No ASA: OR 0.72 (95% CI, 0.56 to 0.93), p=0.01  Age ≥ 60 years: ASA vs. No ASA: OR 0.77 (95% CI, 0.65 to 0.93), p=0.006 |
| No ASA | 149/NR (NR) | 272/NR (NR) |
| Sex | Peto, 1988 (BMD)72 | Group | Women | Men | -- | Between Group Difference |
| ASA | NA | 119/3429 (3.5%) | -- | NR |
| No ASA | 58/1710 (3.4%) |
| Cook, 2005 (WHS)60 | ASA | 1438/19934 (7.2%) | NA | -- | ASA vs. No ASA: RR (95% CI): 1.01 (0.94, 1.08), p=0.87‡ |
| No ASA | 1427/19942 (7.2%) |
| Rothwell, 201210  (IPD MA)  Cancer <3 years | ASA | 176/NR (NR) | 269/NR (NR) | -- | Women: ASA vs. No ASA: OR 1.13 (95% CI, 0.91 to 1.40), p=0.28  Men: ASA vs. No ASA: OR 0.94 (95% CI, 0.80, 1.12), p=0.49 |
| No ASA | 158/NR (NR) | 284/NR (NR) |
| Rothwell, 201210  (IPD MA)  Cancer ≥3 years | ASA | 132/NR (NR) | 192/NR (NR) | -- | Women: ASA vs. No ASA: OR 0.75 (95% CI, 0.59 to 0.94), p=0.01  Men: ASA vs. No ASA: OR 0.77 (95% CI, 0.63 to 0.93), p=0.008 |
| No ASA | 176/NR (NR) | 245/NR (NR) |
| Baseline Cancer Risk | Cook, 2005 (WHS)60† | Group | Family History of Cancer | No Family History of Cancer | -- | Between Group Difference |
| ASA | 264/3529 (7%) | 1174/16405 (7%) | -- | Family History of Cancer: RR 0.94 (95% CI, 0.79 to 1.11), p=0.46‡  No Family History of Cancer: RR 1.02 (95% CI, 0.94 to 1.11), p=0.59‡ |
| No ASA | 280/3517 (8%) | 1147/16425 (7%) |
| Baron, 2003 (AFPPS)77 | Group | Prior Colon Adenoma | -- | -- | Between Group Difference |
| ASA 325 mg | 12/372 (3.2%) | NA | -- | NR |
| ASA 81 mg | 16/377 (4.2%) |
| Placebo | 7/372 (1.9%) |
| Logan, 2008 (ukCAP)68 | ASA | 12/472 (2.5%) | NA | -- | NR |
| No ASA | 15/367 (4.1%) |
| Diabetes | Belch, 2008 (POPADAD)57 | Group | Diabetic | -- | -- | Between Group Difference |
| ASA | 45/638 (7.1%) | NA | -- | NR |
| No ASA | 60/638 (9.4%) |
| de Gaetano, 2001 (PPP)61 | ASA | 93/2226 (4.2%) | NR | -- | NR |
| No ASA | 89/2269 (3.9%) |

Note: Studies reported cancer incidence specific to race/ethnicity subgroups

\*Interaction testing, p=0.32

†Interaction testing, p=0.37

‡Adjusted by age, vitamin E and beta-carotene assignment

**Abbreviations**: ASA = acetylsalicylic acid; CI = confidence interval; HR = hazard ratio; mg = milligram(s); NA = not applicable; NR = not reported; OR = odds ratio; RR = relative risk